Androgen receptor antagonists work by binding to the androgen receptor on the surface of prostate cancer cells. This prevents androgens from binding to the receptor, thereby inhibiting the androgen receptor's activation. This disruption halts the androgen receptor signaling pathways that promote cancer cell growth and survival.